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Antenatal 
corticosteroids to 
reduce preterm deaths 
in low-income settings
Kishwar Azad and Anthony Costello1 
suggest the use of extreme caution in 
scaling up of antenatal corticosteroid 
treatment in low-income settings. 
They raise three important questions 
with respect to the eﬃ  cacy, safety, 
and the appropriate gestational age 
at which to give corticosteroids to 
patients in low-income countries. 
Firstly, in terms of efficacy, there 
is high-quality evidence on the 
benefits of antenatal corticosteroids 
for lung maturation in utero. A large 
decrease in neonatal mortality was 
reported in trials in four middle-
income countries, including those in 
Africa and the Middle East (relative 
risk [RR] 0·47, 95% CI 0·35–0·64), 
compared with 14 studies in high-
income countries (0·79, 0·65–0·96).2,3 
Antenatal corticosteroids actually 
reduced the need for level 2 care, 
including mechanical ventilation or 
continuous positive airway pressure 
in four studies (0·69, 0·53–0·90) 
and intensive care in two studies 
(0·80, 0·65–0·99) suggesting that, in 
regions where mechanical ventilation 
is not available, substantial benefits 
could be expected.2,3 We agree that 
more research is needed but in 
view of the biological basis for the 
effect of antenatal corticosteroids 
on infant mortality, it is extremely 
unlikely, statistically, that antenatal 
corticosteroids would be shown not to 
work in African or Asian babies.
Secondly, we agree with Azad 
and Costello that potential harm to 
the patient is always a critical issue. 
However, a one-oﬀ  course of antenatal 
corticosteroids (<48 h) poses a 
very low risk of adverse effects. The 
Cochrane systematic review2 discussed 
by Azad and Costello shows antenatal 
corticosteroids are associated with 
major reductions in, death, severe 
disability and lower rates of retinopathy 
of prematurity so their concerns with 
respect to perinatal death or disability 
are hard to justify. Repeat antenatal 
corticosteroids have been linked to 
learning disabilities compared with a 
single dose,4 and late-onset metabolic 
syndrome might also be a risk.5   With 
respect to maternal outcomes there 
is no robust evidence of increased 
infections.6  Because preterm deaths are 
now the leading cause of child deaths at 
1 million per year, the balance lies in the 
direction of reducing mortality rather 
than the unknown risks of less severe 
outcomes.
Thirdly, although the proven beneﬁ t 
of antenatal corticosteroids is when 
they are administered to patients 
at 28–33 weeks’ gestation, this 
gestational age band is partly due 
to enrolment criteria in the original 
trials.2,3 The gestational-age limit for 
antenatal corticosteroids in high-
income countries has been extended 
with guidelines supporting use at 
less than 26 weeks’ gestation. More 
than 85% of preterm infants are born 
at least 32 weeks’ gestation,7 and 
although few have major preterm birth 
complications, this amounts to a large 
proportion of infants potentially at 
risk. The upper gestational-age limit for 
corticosteroid use is a critical question 
yet to be answered, especially in 
health-care settings where mechanical 
ventilators are not widely available 
and antenatal corticosteroids are 
more likely to be life-saving. WHO is 
presently review ing the recommended 
upper and lower gestational-age 
cutoffs for antenatal corticosteroid 
treatment. When gestational-age of 
an infant is unknown or is imprecisely 
known, the balance of risks needs to 
be considered and in high mortality 
settings the balance will be in favour of 
treatment. 
High-income countries have at 
least 90% coverage of antenatal 
corticosteroids, with most women 
in preterm labour being treated, and 
clinicians would be sued for non-use. 
Yet countries with the highest rates of 
preterm births have negligible coverage 
of antenatal corticosteroids. We support 
the call for more research, especially 
on how to reach the poorest women 
and how to increase long-term health 
for both women and their babies. In 
the meantime, the evidence strongly 
supports giving a single, short course 
of corticosteroids to women at risk of 
preterm birth in hospitals everywhere, 
not just in high-income countries.
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